Royalty Pharma plc (RPRX) on Decifer

Decifer ranks RPRX number 78 of 275 tracked names on durable business quality.

Why it ranks here

• It earns solid returns on the money it puts to work, around 9% and it turns most of its profit into real cash.
• Revenue is expected to grow about 8% a year, profits grew 21% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• And it returns cash to shareholders.
• Widening margins and profits up 21% with 20 out of 35 momentum in a leading healthcare sector are appealing, but revenue expected to grow about 8% a year and no worldview role cap it.

The current read

The evidence on RPRX lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Healthcare, Biotech & Devices: Royalty Pharma plc operates in medical - pharmaceuticals. That places it inside the Healthcare, Biotech & Devices story.

Read the full RPRX research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.